Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 6/20 | 1.00 |
| ▸ | SRD5A2 | P31213 | 6/20 | 1.00 |
| ▸ | CNR1 | P21554 | 3/20 | 0.49 |
| ▸ | CNR2 | P34972 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3504489 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2CNR1CNR2MAPT | |
| Hydrochloric Acid SCHEMBL8793978 | 0.99 | SRD5A1 (0.98) | SRD5A1SRD5A2CNR1CNR2MAPT | |
| SCHEMBL8793523 | 0.97 | SRD5A1 (0.95) | SRD5A1SRD5A2CNR1CNR2MAPT | |
| N-Phenylbenzamide SCHEMBL6762152 | 0.95 | SRD5A1 (0.91) | SRD5A1SRD5A2CNR1CNR2MAPT | |
| SCHEMBL9386762 | 0.95 | SRD5A1 (0.91) | SRD5A1SRD5A2CNR1CNR2 | |
| SCHEMBL8792770 | 0.95 | SRD5A1 (0.90) | SRD5A1SRD5A2CNR1CNR2MAPT | |
| SCHEMBL8793385 | 0.93 | SRD5A1 (0.88) | SRD5A1SRD5A2CNR1CNR2MAPT | |
| SCHEMBL9336300 | 0.93 | SRD5A1 (0.86) | SRD5A1SRD5A2CNR1CNR2MAPT | |
| SCHEMBL9337867 | 0.91 | SRD5A1 (0.84) | SRD5A1SRD5A2CNR1CNR2MAPT | |
| SCHEMBL8792545 | 0.91 | SRD5A1 (0.83) | SRD5A1SRD5A2CNR1CNR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3220942-B1 | COMPOSITIONS COMPRISING LOW DOSE DESMOPRESSIN IN COMBINATION WITH AN ALPHA-ADRENERGIC RECEPTOR ANTAGONIST | SERENITY PHARMACEUTICALS LLC (US) | 2022-04-27 | — | — | EP | claimed |
| US-20250295634-A1 | USE OF ANTIANDROGENS TO TREAT SEPSIS | RHODE ISLAND HOSPITAL | 2025-09-25 | — | — | US | disclosed |
| EP-3220942-B1 | COMPOSITIONS COMPRISING LOW DOSE DESMOPRESSIN IN COMBINATION WITH AN ALPHA-ADRENERGIC RECEPTOR ANTAGONIST | SERENITY PHARMACEUTICALS LLC (US) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295634-A1 | USE OF ANTIANDROGENS TO TREAT SEPSIS | SHBG, AR, HSD17B11 | SRD5A1 12/4885SRD5A2 11/4885CNR1 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.